Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASANEW ORLEANS — Once-daily orforglipron induced greater reductions in HbA1c than dapagliflozin and oral semaglutide for adults with type 2 diabetes, according to findings from the ACHIEVE-2 and ACHIEVE-3 trials.As Healio previously reported from the ACHIEVE-1 trial, orforglipron (Foundayo, Eli Lilly), a small molecule oral GLP-1, conferred greater decreases in HbA1c and body weight at 40 weeks than placebo for adults with type 2 diabetes. In new data from ACHIEVE-2 and ACHIEVE-3, researchers compared efficacy of orforglipron in the type 2 diabetes populations with the SGLT2 inhibitor
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Novel oral GLP-1 confers glucose, weight reduction | 5 | 7 | 23-06-2026 |
| 2 | Semaglutide may reduce fracture risk in type 2 diabetes | 0 | 5 | 24-06-2026 |
| 3 | Ozempic tied to improved quality of life in type 2 diabetes, CKD | 0 | 0 | 12-06-2026 |
| 4 | GLP-1 RAs do not improve migraines | 0 | 6 | 19-06-2026 |
| 5 | Сахарный диабет 2-го типа и коморбидные состояния: от клинических рекомендаций к повседневной практике | 0 | 0 | 19-06-2026 |
| 6 | Stanford researchers say your body already makes this Ozempic alternative | 0 | 7 | 15-06-2026 |
| 7 | GLP-1s linked to elevated rates of hypotensive events | 0 | 0 | 13-06-2026 |
| 8 | Sleep Apnea May Amplify GLP-1 Survival Benefits in Type 2 Diabetes | 0 | 0 | 23-10-2025 |
| 9 | The 'biohacking' trend that has tech workers experimenting on themselves | 0 | 6 | 19-01-2026 |
| 10 | ‘Next major revolution’: The rise of targeted oral psoriasis therapies | 5 | 7 | 23-06-2026 |